Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Update symbols : Admp save search
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-08-21 (Crawled : 13:20) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: -13.24%
H: 10.73%
C: 0.55%
update pharmaceuticals financial results
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-05-15 (Crawled : 21:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 21.43%
H: 0.0%
C: -18.24%
update pharmaceuticals financial results
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
Published: 2023-05-08 (Crawled : 20:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 2.39%
H: 0.0%
C: -3.85%
conference update pharmaceuticals financial results
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-16 (Crawled : 21:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 4.64%
H: 0.0%
C: -12.97%
year update pharmaceuticals financial results
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
Published: 2023-03-14 (Crawled : 20:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 1.76%
H: 6.7%
C: -1.97%
pharmaceuticals conference year financial update results
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-14 (Crawled : 21:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.0%
H: 29.44%
C: 19.44%
pharmaceuticals financial update results
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
Published: 2022-09-21 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: -44.42%
H: 35.14%
C: 29.08%
covid-19 trial positive update phase 2
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
Published: 2022-09-12 (Crawled : 22:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 2.87%
H: 9.68%
C: 6.03%
covid-19 positive update study phase 2
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
Published: 2022-08-08 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 4.28%
H: 0.0%
C: -3.87%
conference update results
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19Interim DSMB review expected in late September
Published: 2022-07-29 (Crawled : 12:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.94%
H: 4.9%
C: 3.4%
covid-19 treatment expected review update study
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Published: 2022-07-29 (Crawled : 12:00) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.94%
H: 4.9%
C: 3.4%
covid-19 treatment update study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.